博瑞醫藥(688166.SH)再創新高 稱對瑞德西韋尚處研發階段不存在侵權
格隆匯2月14日丨此前連續兩日一字漲停(累漲44%)的博瑞醫藥(688166.SH)今日繼續上漲,盤中一度創72.38元上市新高價,現報66.12元,漲5.72%,暫成交9.35億元,最新總市值273億元。該股去年11月8日以12.71元IPO價格上市,截至目前的3個月間累漲幅度高達420%。

在國外被用於防治埃博拉病毒感染的瑞德西韋,被寄予抗擊新冠肺炎的厚望。2月11日晚,博瑞醫藥發公告稱,近日成功仿製開發了瑞德西韋原料藥合成工藝技術和製劑技術。公司已批量生產出瑞德西韋原料藥,瑞德西韋製劑批量化生產正在進行中。
針對近日有市場傳聞,公司開發瑞德西韋涉嫌侵犯專利權。博瑞醫藥最新迴應稱,截至目前,公司關於瑞德西韋的開發工作尚處於研發階段,公司認為上述研發事宜不存在侵犯專利權的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.